Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1126893 | 0.85 | KMT2A (0.53) | CYP1A2CYP2C19SMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL1127342 | 0.85 | CYP1A2 (0.48) | CYP1A2CYP2C19SMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL1126963 | 0.80 | MEN1 (0.53) | CYP1A2CYP2C19SMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL20049003 | 0.77 | MEN1 (0.44) | CYP1A2CYP2C19SMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL22152871 | 0.76 | MEN1 (0.40) | CYP1A2CYP2C19SMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL13009146 | 0.76 | LMNA (0.51) | CYP1A2CYP2C19SMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL28046090 | 0.76 | KMT2A (0.46) | KDM4EHSD17B10MAPK1KMT2AMEN1 | |
| SCHEMBL3771942 | 0.76 | RXFP1 (0.50) | CYP1A2CYP2C19SMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL30464227 | 0.76 | RXFP1 (0.50) | CYP1A2CYP2C19SMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL29816603 | 0.75 | CYP3A4 (0.54) | CYP1A2CYP2C19SMN1; SMN2KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020125615-A1 | C-TERMINAL SRC KINASE INHIBITORS | INVENTISBIO SHANGHAI LTD. (CN) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020124397-A1 | C-TERMINAL SRC KINASE INHIBITORS | INVENTISBIO SHANGHAI LTD. (CN) | 2020-06-25 | — | — | WO | disclosed |
| US-10421761-B2 | Compounds for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-10421761-B2 | Compounds for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20180099975-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099975-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| US-9873700-B2 | Compounds for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873700-B2 | Compounds for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| WO-2011059610-A1 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011059610-A1 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-05-19 | — | — | WO | disclosed |
| EP-2282636-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| WO-2009137391-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137391-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | STS, TST, TPST2 | CYP1A2 111/4885CYP2C19 56/4885SMN1; SMN2 2314/4885 |
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | CYP1A2 111/4885CYP2C19 56/4885SMN1; SMN2 2314/4885 |
| US-10421761-B2 | Compounds for kinase modulation, and indications therefor | MAP3K20, MAP3K13, MAP3K8 | CYP1A2 4739/4885CYP2C19 4598/4885SMN1; SMN2 1530/4885 |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | CYP1A2 111/4885CYP2C19 56/4885SMN1; SMN2 2314/4885 |
| US-20180099975-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CYP1A2 4739/4885CYP2C19 4598/4885SMN1; SMN2 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.